Patient Guide: A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 165 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT03653507
Status: ACTIVE_NOT_RECRUITING
Condition: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase: PHASE3

Find a Study Location Near You

This study is available at 165 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Monterey, California
  • Fairway, Kansas
  • New Orleans, Louisiana
  • • And 162 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily